The combination of the antisense STAT3 oligonucleotide danvatirsen with α-PD-L1 therapy (durvalumab) in HNSCC patients improved response rates over those in historic controls treated with α-PD-L1 therapy alone [147]. Here, STAT3 is linked to head and neck squamous cell carcinoma.